Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide

Pegfilgrastim for prevention of chemotherapy‐associated neutropenia in pediatric patients with solid tumors

“…Because our patients received a wide variety of chemotherapy regimens, it is not possible to determine the expected frequency of severe neutropenia and febrile neutropenia. However, the observed frequency of these toxicities was similar to that reported for common pediatric sarcoma regimens with filgrastim support [17][18][19]. In addition, sarcoma patients treated with interval compressed chemotherapy every 2 weeks had interval durations and febrile neutropenia frequency similar to published data with filgrastim [19,20].…”

“…Based upon an institutional policy change in January 2007, all patients received pegfilgrastim after myelosuppressive chemotherapy instead with three exceptions: patients less than 2 months old, patients with planned peripheral blood stem cell collection, and patients enrolled on investigational drug trials requiring the use of filgrastim. Our patients received a wide range of chemotherapy regimens [17][18][19][20][21][22][23][24][25][26]. To avoid the confounding effect of local control surgery or radiotherapy on toxicity and chemotherapy interval, we evaluated only the first four courses of myelosuppressive chemotherapy for each eligible patient, similar to the methodology reported by Fox et al [15].…”

Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS‐II through ‐IV, 1978–1997*†

“…One report discussed nine patients with cranial parameningeal sarcoma and meningeal involvement whose radiation therapy was delayed for up to 12 weeks, provided that chemotherapy was effective [20]. This information has to be interpreted with caution, as we have shown that the cumulative incidence of primary CNS failure is only 7% when XRT is begun at the time of diagnosis in those with meningeal involvement.…”

Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma

“…One of the most frequently used chemotherapeutics in the treatment of human sarcoma is cyclophosphamide (CPA; Refs. [7][8][9]. However, even with CPA response rates do not exceed 28% (7).…”